Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TAS 114

Next Previous
Drug Profile

TAS 114

Alternative Names: TAS-114

Latest Information Update: 25 Feb 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taiho Pharmaceutical
  • Developer National Cancer Center Hospital East; Taiho Pharmaceutical
  • Class Antineoplastics
  • Mechanism of Action Dihydropyrimidine dehydrogenase inhibitors; DUTP pyrophosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer; Non-small cell lung cancer
  • No development reported Solid tumours

Most Recent Events

  • 25 Feb 2021 TAS 114 is still in phase II development for Non-small cell lung cancer in USA, Japan and EU (Taiho Pharmaceutical pipeline, February 2021)
  • 27 Sep 2019 Safety and efficacy data from a phase II trial in advanced Gastric cancer presented at the 44th European Society for Medical Oncology Congress (ESMO-2019)
  • 10 Jan 2019 National Cancer Center Hospital East and Taiho Pharmaceuticals completes a phase II trial in Gastric cancer (Combination therapy, Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable, Metastatic disease, Recurrent) in Japan (PO) (UMIN000028329) (700288577.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top